T
CRL icon

Tidemark’s Charles River Laboratories CRL Stock Holding History

Tidemark’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9K Buy
26
+1
+4% +$178 ﹤0.01% 576
2026
Q1 		$4.31K Hold
25
– – ﹤0.01% 573
2025
Q4 		$4.99K Hold
25
– – ﹤0.01% 503
2025
Q3 		$3.91K Hold
25
– – ﹤0.01% 548
2025
Q2 		$3.79K Hold
25
– – ﹤0.01% 551
2025
Q1 		$3.76K Hold
25
– – ﹤0.01% 563
2024
Q4 		$4.62K Hold
25
– – ﹤0.01% 518
2024
Q3 		$4.92K Hold
25
– – ﹤0.01% 492
2024
Q2 		$5.17K Hold
25
– – ﹤0.01% 466
2024
Q1 		$6.77K Hold
25
– – ﹤0.01% 485
2023
Q4 		$5.91K Buy
+25
New +$4.92K ﹤0.01% 483

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Tidemark's CRL Position: Q2 2026 in Review

Tidemark increased its Charles River Laboratories (CRL) stake by 4% in Q2 2026, buying an estimated $178 and bringing the position to 26 shares worth $5.9K. The position accounts for ﹤0.01% of the portfolio, ranked #576.

Tidemark first reported a position in CRL in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.77K in Q1 2024. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Tidemark held 26 shares of Charles River Laboratories worth $5.9K as of Q2 2026.
  • Tidemark bought 1 Charles River Laboratories share in Q2 2026, an estimated $178.
  • Charles River Laboratories made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #576 holding.
  • Tidemark first reported a position in Charles River Laboratories in Q4 2023 and has held it in 11 quarters since.
  • Tidemark's Charles River Laboratories position peaked at $6.77K in Q1 2024.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.